ArticleBMC gastroenterology2025
The effectiveness of radiotherapy and transarterial embolization for advanced gastric cancer bleeding.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The prognostic role of radiotherapy in non-surgical gastric cancer: a retrospective cohort study in the SEER database.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced gastric cancer frequently leads to severe complications, such as bleeding, which severely impacts patients' quality of life and prognosis. Traditional approaches for hemostasis include endoscopic treatments and surgery, but their invasive nature and potential for significant morbidity have made less invasive options like radiation therapy (RT) and transarterial embolization (TAE) appealing. Nonetheless, studies comparing the therapeutic effects and prognosis of RT and TAE are limited, underscoring a significant gap in research and clinical practice.
methodsThis retrospective study analyzed patients with advanced gastric cancer who experienced uncontrollable bleeding and were treated with RT or TAE. The efficacy of these treatments was assessed based on the achievement of hemostasis, defined as the absence of the need for blood transfusion within 14 days post-treatment and no requirement for additional intervention for bleeding. Furthermore, the study evaluated the post-treatment course, including survival outcomes and re-bleeding rates, to compare the prognostic implications of treatment success or failure.
resultsThis study encompassed 28 patients, of whom 19 underwent RT and 9 received TAE. RT was associated with a superior rate of immediate hemostasis (94.7% versus 66.7%, p = 0.047). Nonetheless, the incidence of re-bleeding in the RT cohort was 15.8%, compared to 44.4% in the TAE group, a difference that did not reach statistical significance (p = 0.11). Furthermore, the occurrence of adverse events was comparable between the two treatment modalities (21.1% for RT versus 33.3% for TAE, p = 0.48). An examination of long-term outcomes underscored the initial treatment's effectiveness and the potential transition to additional therapies as critical determinants of the re-bleeding risk. Groups achieving favorable initial outcomes (p < 0.001) and those for whom subsequent interventions were viable (p = 0.014) demonstrated a significant enhancement in re-bleeding-free survival. Despite the discrepancy in rates of immediate hemostasis, the comparison between the RT and TAE groups revealed no statistically significant difference in re-bleeding-free survival (p = 0.55).
conclusionRT exhibited superior hemostasis in advanced gastric cancer bleeding compared to TAE, yet both treatments showed similar re-bleeding-free survival rates. The success of the initial treatment, along with potential for further interventions, critically influenced outcomes, emphasizing the importance of effective initial hemostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.